A review and assessment of potential sources of ethnic differences in drug responsiveness.
about
Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences.Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine.Influence of ethnic origin and sex on the pharmacokinetics of clazosentan.Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy.Globalization of Alzheimer's disease clinical trialsComparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trialsSingle and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial.Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects.Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjectsDifferences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trialsDuloxetine pharmacokinetics are similar in Japanese and Caucasian subjects.Support and undermining in interpersonal relationships are associated with symptom improvement in a trial of antidepressant medication.Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes.Translating genomic biomarkers into clinically useful diagnostics.Antifactor Xa levels in critically ill Korean patients receiving enoxaparin for thromboprophylaxis: a prospective observational study.A population-based analysis of the health experience of African Nova ScotiansEthnicity and psychopharmacology.Investigation of CYP2D6 Gene Polymorphisms in Turkish PopulationFactors influencing physician referrals of patients to clinical trialsRacial/ethnic differences in drug disposition and response: review of recently approved drugs.Design of a cluster-randomized minority recruitment trial: RECRUIT.Safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod in healthy Japanese volunteers.Evaluating the Responsiveness to Therapeutic Change with Routine Outcome Monitoring: A Comparison of the Symptom Questionnaire-48 (SQ-48) with the Brief Symptom Inventory (BSI) and the Outcome Questionnaire-45 (OQ-45).What race and ethnicity measure in pharmacologic research.Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men.Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption.Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation.Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects.Statin effects on LDL and HDL cholesterol in South Asian and white populations.Ethnicity and trial recruitment.Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjects.The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine.Race and ethnicity in the era of emerging pharmacogenomics.Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations.Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients.
P2860
Q31049674-640553AD-88F7-46A3-B97F-CEF7D16FBB79Q33433942-B41F8BEF-F7C4-4442-800B-D9A10644CC81Q34623044-62CDE506-1F19-46CE-99F4-C3B0E9A37C8EQ34655124-885BB6D1-1104-46D6-8E0D-96AAE382DCAEQ35224900-DBAB68C0-50D4-449E-8419-BD53DE2CF7E7Q35443771-77236BA0-FDA0-4DD3-AA19-8C23A6BA6C20Q35579247-DB825DBC-D721-4B6E-9144-FAF5174E6FD4Q35782753-8DE4A716-641C-4D30-AED9-F6C2AE478DC2Q35806392-D8B19E8C-F22B-4710-9D71-EBD437B94564Q35827520-7BC7BE86-F5D0-4D17-8A94-4E68BE398F3FQ35827907-D0BB1E5C-4144-4D79-B822-F0DC95C68D65Q35876954-4EB7B8D8-9853-4B80-8E10-6EFE74C666BFQ35878541-87A3ED10-E118-4618-BEE5-B6E84A6DD7A2Q36024984-2F04820A-F629-44A1-940D-EE9DC6935EFEQ36029953-00293B7E-282A-4B5C-A4A3-7106292E6D30Q36256056-9E18A110-E600-4502-982B-311765EC1DDDQ36411676-D7CC4167-17C3-4331-BB0C-265ACC34E35BQ36675594-787EAAC4-6E67-4F0E-AB5F-F98B35AC0321Q36873865-AA2E2E78-9161-4C96-94E9-3EBCFCFC1011Q37097622-88DDCA15-578F-4330-9CD1-86FDD2BFACC2Q37299922-2952E3ED-DA86-4DFE-BD91-40E4D959927AQ37454491-1FB15238-305C-4CBB-B0D1-94C67C876722Q38351175-FD0FC44E-AABB-4645-90D1-B4403992C93FQ38763336-C606EB99-BD63-4369-8D94-758356BB6643Q39802639-79CE8F5E-0DD4-4122-8F6C-891AD964FC5DQ40450491-51EFEAD1-4F86-49B5-B568-37FC83FAF4C5Q42562703-C1F65C39-CB22-4A53-B946-2ACAFFE6C4EAQ42614556-4D7301AB-85FB-4D5C-B7E5-AF52C48735EEQ43676406-F9442EA0-81FE-4D48-9DBF-D6F4CB371100Q43699242-0DC9DD13-9FC2-4C45-AEAC-1352B6A6857AQ45169488-0306A1DB-3233-4C40-B03E-BE682D2B158BQ45188822-4D94748B-5A71-49D8-99AD-7A2215953BEBQ46034432-1D0FC601-7A6F-4F2E-933F-1335BFAC0A3BQ46072281-296F0765-9180-40FD-B4E4-BEF4621B46E6Q46862790-C31ED196-E20D-46E9-BD1A-3981CC092694Q46886423-71699E6C-63D0-40F1-8D3E-D619F8754152Q47216691-6140813E-FFB0-41A0-80BE-7B6EA2561ADCQ47329745-0622C790-AF68-4BC1-A9D3-0A17A5B4EAFEQ47404372-049A3B74-B668-4803-8B5A-CBB7F2BDA08FQ47877438-E268497F-8515-43D5-9F6D-0F5802CDCFE6
P2860
A review and assessment of potential sources of ethnic differences in drug responsiveness.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A review and assessment of pot ...... rences in drug responsiveness.
@ast
A review and assessment of pot ...... rences in drug responsiveness.
@en
type
label
A review and assessment of pot ...... rences in drug responsiveness.
@ast
A review and assessment of pot ...... rences in drug responsiveness.
@en
prefLabel
A review and assessment of pot ...... rences in drug responsiveness.
@ast
A review and assessment of pot ...... rences in drug responsiveness.
@en
P2093
P2860
P356
P1476
A review and assessment of pot ...... rences in drug responsiveness.
@en
P2093
Aziz Karim
Caroline Loew
Daryl S Sonnichsen
Dawn Harper
Dennis J Stalker
Dennis Schneck
John A Wagner
Kristin Roman
Marlene S Khouri
Stephen D Wise
P2860
P304
P356
10.1177/0091270003256065
P577
2003-09-01T00:00:00Z